Tag: Dosed

NORTH BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics ...

Novel preventative AT-100 offers potential to reduce incidence and severity of serious respiratory disease BPD, improving outcomes in very preterm infants MARIETTA, Ga., March 31, 2022 /PRNewswire/ -- Airway Therapeutics, ...

First patient dosed in Phase III clinical trial for PET radiopharmaceutical Next stage clinical study also proceeding for SPECT radiopharmaceutical Both imaging agents aim to assist in the evaluation of ...

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (“CANbridge,” stock code 1228.HK), a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology ...

Lund Sweden, February 7, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the combination part of the phase Ib/IIa clinical study ...

ImCheck Announces First Patients Dosedin Phase II of EVICTION Trial for ICT01          EVICTION trial proceeds to Phase IIa based on promising Phase I patient datafor ICT01 across a broad ...

MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s prostate-specific membrane ...

SHANGHAI, China and SUZHOU, China and GERMANTOWN, Md., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer ...

Phase 2 trial to evaluate reduction in heavy drinking as measured by a change in the World Health Organization drinking risk levels1 Trial is informed by results from Phase 1 ...

-- DAYBREAK is the most comprehensive Phase 2 trial ever initiated in rare genetic diseases of obesity ---- DAYBREAK is evaluating setmelanotide in patients with severe obesity and hyperphagia caused ...